This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Dec. 6, 2012 /PRNewswire/ -- Amarantus Bioscience, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that it will be presenting at the
OneMedForum 2013 healthcare conference on
Tuesday, January 8th, 2013 at
. OneMedForum 2013 will be held at the Sir Francis Drake Hotel during the week of the J.P. Morgan 31
st Annual Healthcare Conference in
San Francisco. A link to the live webcast of the presentation will be made available to the public prior to the conference.
Established in 2008,
OneMedForum is the conference component of OneMedPlace, which provides an integrated media platform to showcase the best ideas and innovations in health and medicine globally. The media platform also includes: OneMedRadio; OneMedTV, OneMedSentinel; a global database of companies; and OneMedResearch, which tracks promising lesser-known microcap public companies. For more information visit the conference website.
www.onemedforum.comAbout Amarantus Bioscience, Inc.
Amarantus Bioscience, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit
Forward Looking Statements